Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

B&L lawsuits

This article was originally published in The Tan Sheet

Executive Summary

Bausch & Lomb is facing at least two lawsuits alleging that consumers who used the company's Renu with MoistureLoc contact lens solution sustained injuries such as fungal infections. A Florida suit seeks $75,000 in damages, while a complaint in New York motions to enjoin B&L from distributing the product. Both suits seek class action status and were filed April 17. The company asked retailers to remove all products containing MoistureLoc from store shelves April 13 after FDA and the Centers for Disease Control & Prevention announced they were investigating 109 cases of Fusarium keratitis, some of which may be linked to use of Renu with MoistureLoc (1"The Tan Sheet" April 17, 2006, p. 5). B&L demonstrated "conscious and callous disregard for the safety of consumers and the public," the New York suit alleges...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel